Candriam S.C.A. Sells 18,583 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Candriam S.C.A. trimmed its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 2.5% in the 4th quarter, HoldingsChannel reports. The firm owned 731,221 shares of the company’s stock after selling 18,583 shares during the period. Candriam S.C.A.’s holdings in Viridian Therapeutics were worth $14,018,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. FMR LLC increased its holdings in shares of Viridian Therapeutics by 16.8% in the third quarter. FMR LLC now owns 11,183,478 shares of the company’s stock worth $254,424,000 after purchasing an additional 1,610,130 shares during the last quarter. Parkman Healthcare Partners LLC bought a new stake in Viridian Therapeutics in the third quarter worth $9,669,000. Victory Capital Management Inc. purchased a new position in Viridian Therapeutics during the fourth quarter worth $7,868,000. Lord Abbett & CO. LLC purchased a new stake in shares of Viridian Therapeutics in the third quarter valued at $8,917,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Viridian Therapeutics in the 4th quarter worth about $6,015,000.

Viridian Therapeutics Trading Up 3.9 %

NASDAQ VRDN opened at $15.88 on Friday. Viridian Therapeutics, Inc. has a 52 week low of $11.40 and a 52 week high of $27.20. The company has a 50 day moving average price of $17.86 and a 200 day moving average price of $19.64. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.26 billion, a PE ratio of -3.68 and a beta of 1.05.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. As a group, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VRDN has been the topic of several analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. TD Cowen assumed coverage on shares of Viridian Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating on the stock. Royal Bank of Canada boosted their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Finally, HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of Viridian Therapeutics in a research report on Monday, December 16th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $35.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.